CD19 CAR-T Cells for Treatment-Refractory Autoimmune Diseases: The Phase I/II CASTLE Basket Trial

The CAR-T cells in systemic B cell mediated autoimmune disease (CASTLE) study investigated the safety and efficacy of zorpocabtagene autoleucel in patients with treatment-resistant systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies.